Adalvo announces the continued rollout of its Solifenacin/Tamsulosin fixed-dose combination across key markets in both Europe and Latin America, reinforcing its position as a commercial leader in urology with a global launch strategy.
Following its successful first-to-market entry in LATAM earlier this year, Adalvo is now expanding access across additional European & LATAM countries, delivering a complex, high-value therapy to address an area of growing clinical need.
Developed as a bioequivalent to Vesomni MR Tablets (6mg/0.4mg), the product is indicated for the treatment of moderate to severe storage and voiding symptoms associated with benign prostatic hyperplasia (BPH) in men, an increasingly prevalent condition with a significant impact on quality of life.
This dual-regional expansion showcases Adalvo’s ability to execute coordinated launches across diverse markets, supported by a clear regulatory and IP pathway. Adalvo continues to prioritise early market entry for partner-ready assets, enabling both mature and emerging markets to benefit from differentiated treatments.
According to IQVIA, global sales for Solifenacin/Tamsulosin reached approximately $109 million in 2024, reflecting sustained demand and commercial relevance.
With further launches planned, Adalvo remains committed to delivering high-barrier, strategically developed products that bring meaningful value to patients, partners, and healthcare systems worldwide.
To explore licensing or commercial opportunities for Solifenacin/Tamsulosin or within Adalvo’s urology portfolio, contact the team today.